Amphion confirms settlement of loan facility through sale of Polarean holding
18th Oct 2019 12:01
(Sharecast News) - Medical, life sciences and technology businesses developer Amphion Innovations announced on Friday that, further to the sale of its total holding of 15,972,523 shares in Polarean Imaging as announced on 11 October, the lender of the facility has subsequently confirmed that the total net proceeds arising from the sale were $2.6m.
Read moreAmphion Innovations sells 1.8m shares in Motif Bio
15th Mar 2019 14:31
(Sharecast News) - Medical technology business developer Amphion Innovations announced on Friday that 1,825,000 shares in its partner company, Motif Bio, had been sold in partial repayment of the loan facility originally announced on 5 June 2014, and most recently amended on 11 March.
Read moreMotif Bio crashes as FDA calls for more data
14th Feb 2019 11:47
(Sharecast News) - Motif Bio said it will need to raise new funds after the application for its skin infections treatment, iclaprim, was refused by the US drug regulator in its present form.
Read moreAmphion Innovations still considering funding options
7th Feb 2019 08:55
(Sharecast News) - Amphion Innovations said on Thursday that it was not aware of any reason for the recent movement in its share price and that it is still considering its funding options.
Read moreAmphion draws down on loan, notes possible Motif Bio IPO
13th Jul 2016 14:12
(ShareCast News) - Medical, life science and technology business developer Amphion Innovations announced on Wednesday that it has agreed terms for the drawdown of an additional tranche of $0.75m under the loan facility first announced on 5 June 2014. The AIM-traded company said it will receive the p
Read moreAmphion increases NAV through Motif Bio investment
23rd Jun 2016 13:27
(ShareCast News) - Medical and technology business developer Amphion Innovations announced its audited results for the 2015 calendar year on Thursday, in which it increased its net asset value per ordinary share in the company by 0.7p to 3.8p. The AIM-traded firm raised £2.1m during the period, thro
Read moreAmphion Innovations buys itself time over promissory notes
5th Jan 2016 11:06
(ShareCast News) - Amphion Innovations worked to assure investors on Tuesday it had bought itself some time over its promissory notes. The AIM-listed developer of medical and technology businesses reported on a meeting of the holders of the company's unsecured convertible promissory notes, which was
Read moreAmphion Innovations announces m2m merger
5th Nov 2015 15:13
(ShareCast News) - Amphion Innovations has signed a memorandum of understanding to merge its partner company m2m Imaging Corp with an undisclosed pulmonary imaging technology. Amphion, which develops medical, life science and technology businesses, said it expects to own around 40% of the combined m
Read moreMotif Bio makes AIM debut, seeks approval for Iclaprim treatment
2nd Apr 2015 11:46
Clinical stage biopharmaceutical group Motif Bio began trading on AIM on Thursday, after raising £2.8m in its initial public offering. The group, whose 44.09% of issued equity is owned by Amphion, placed shares at 20p each, said it had 64,238,442 ordinary shares in issue and a market capitalisation
Read moreAmphion Innovations' part-owned partner lines up AIM flotation
19th Jan 2015 15:08
Amphion Innovations, a developer of medical and technology businesses, announced its part-owned US partner Motif BioSciences will merge with a private company. The private company holds the intellectual property and rights to a clinical stage antibiotic against MRSA and multi-drug resistant bacteria
Read moreAmphion wins key judgement in patent infringement appeal
6th Jan 2015 08:27
Shares in AIM-listed Amphion were flying on Tuesday after the technology business won a key patent decision in the US courts. The company had appealed to the US court of appeal as it felt the '502 patent', owned by its subsidary DataTern, had been infringed by several companies. The federal circuit
Read moreMwana Africa directors cheer results success
10th Jul 2014 16:05
Mining and development group Mwana Africa said its Non-Executive Interim Chairman had on Thursday acquired himself £15,068-worth of shares, growing his stake by around a fifth. Stuart Morris, who has been on the board since 2005, paid 2.55p for each of the 590,910 shares. The purchase, which inc
Read moreAmphion Innovations jumps on back of Kromek AIM float
12th Sep 2013 14:09
A proposed London flotation for one of its investments invigorated shares in private equity incubator Amphion Investments. Amphion, which invests in small medical and technology companies with promising intellectual property, jumped on the news that Durham University spin-out Kromek intends to flo
Read moreShanta Gold director builds stake after strong results
18th Apr 2013 16:27
Shanta Gold, an AIM-listed miner, announced Thursday that Luke Leslie, a Non-Executive Director of the company, bought 193,891 shares. Leslie, who joined the board in August last year, bought the shares at 13p each for a total of £25,206. On Monday the East Africa focused gold producing company
Read moreVectura director exercises options after milestone payment
28th Sep 2012 17:17
Shares of Cambridge-based Vectura rose after it confirmed the Japanese government has approved its Seebri inhalation capsules used in inhaler devices. The shares rose 2p to 86.5p, on news that government clearance will trigger a £2.5m milestone payment for Vectura from its partner Novartis. Whethe
Read more